Jeff Yass’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-28,746
Closed -$31K 14488
2022
Q1
$31K Buy
28,746
+17,205
+149% +$13K ﹤0.01% 12498
2021
Q4
$8K Buy
+11,541
New +$9.34K ﹤0.01% 12963
2021
Q2
Sell
-88,003
Closed -$184K 13570
2021
Q1
$184K Buy
88,003
+75,126
+583% +$156K ﹤0.01% 11494
2020
Q4
$16K Buy
+12,877
New +$15.4K ﹤0.01% 10899
2020
Q3
Sell
-19,814
Closed -$23K 11388
2020
Q2
$23K Buy
19,814
+4,367
+28% +$4.04K ﹤0.01% 9906
2020
Q1
$13K Buy
+15,447
New +$16.4K ﹤0.01% 10012
2019
Q4
Sell
-23,649
Closed -$33K 10989
2019
Q3
$33K Buy
23,649
+3,578
+18% +$5.05K ﹤0.01% 9881
2019
Q2
$30K Buy
+20,071
New +$31K ﹤0.01% 9946
2017
Q2
Sell
-11,224
Closed -$22K 10055
2017
Q1
$22K Buy
+11,224
New +$23.8K ﹤0.01% 8719
2015
Q4
Sell
-65,740
Closed -$139K 10177
2015
Q3
$139K Sell
65,740
-45,856
-41% -$89.3K ﹤0.01% 8966
2015
Q2
$221K Buy
+111,596
New +$316K ﹤0.01% 9120
2014
Q3
Sell
-10,294
Closed -$120K 10114
2014
Q2
$120K Buy
+10,294
New +$117K ﹤0.01% 9355

Other funds holding MBII

Jeff Yass's MBII Position: Q2 2022 in Review

Jeff Yass sold out of Marrone Bio Innovations, Inc. (MBII) in Q2 2022, closing a stake of 28,746 shares — an estimated $31K sold.

Jeff Yass first reported a position in MBII in Q2 2014 and held it in 12 quarters. The position peaked at $221K in Q2 2015. 62 funds tracked by Wall St. Rank hold MBII as of Q2 2022.

  • Jeff Yass reported no remaining Marrone Bio Innovations, Inc. position as of Q2 2022 after selling out during the quarter.
  • Jeff Yass sold 28,746 Marrone Bio Innovations, Inc. shares in Q2 2022, an estimated $31K.
  • Jeff Yass first reported a position in Marrone Bio Innovations, Inc. in Q2 2014 and held it in 12 quarters.
  • Jeff Yass's Marrone Bio Innovations, Inc. position peaked at $221K in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.